Ferguson Wellman Capital Management Inc. Sells 1,039 Shares of Bristol-Myers Squibb (NYSE:BMY)

Ferguson Wellman Capital Management Inc. decreased its holdings in Bristol-Myers Squibb (NYSE:BMY) by 2.0% during the 1st quarter, HoldingsChannel reports. The firm owned 51,653 shares of the biopharmaceutical company’s stock after selling 1,039 shares during the quarter. Ferguson Wellman Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $3,150,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Wealthspire Advisors LLC boosted its stake in Bristol-Myers Squibb by 0.6% in the fourth quarter. Wealthspire Advisors LLC now owns 28,679 shares of the biopharmaceutical company’s stock valued at $1,622,000 after buying an additional 170 shares in the last quarter. Bedel Financial Consulting Inc. boosted its stake in shares of Bristol-Myers Squibb by 3.2% in the 4th quarter. Bedel Financial Consulting Inc. now owns 5,690 shares of the biopharmaceutical company’s stock valued at $340,000 after purchasing an additional 175 shares in the last quarter. King Wealth Management Group grew its holdings in shares of Bristol-Myers Squibb by 2.6% during the 4th quarter. King Wealth Management Group now owns 7,294 shares of the biopharmaceutical company’s stock valued at $413,000 after purchasing an additional 182 shares during the last quarter. Signet Investment Advisory Group Inc. increased its position in Bristol-Myers Squibb by 2.3% during the 4th quarter. Signet Investment Advisory Group Inc. now owns 8,261 shares of the biopharmaceutical company’s stock worth $467,000 after purchasing an additional 189 shares in the last quarter. Finally, Thoroughbred Financial Services LLC boosted its position in Bristol-Myers Squibb by 1.1% in the fourth quarter. Thoroughbred Financial Services LLC now owns 17,763 shares of the biopharmaceutical company’s stock valued at $1,004,000 after buying an additional 190 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Transactions at Bristol-Myers Squibb

In related news, EVP Samit Hirawat acquired 4,250 shares of the business’s stock in a transaction dated Friday, April 25th. The shares were bought at an average price of $47.58 per share, with a total value of $202,215.00. Following the transaction, the executive vice president now directly owns 83,513 shares of the company’s stock, valued at $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.09% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on BMY shares. Cantor Fitzgerald reiterated a “neutral” rating and issued a $55.00 price target on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. The Goldman Sachs Group reiterated a “neutral” rating and issued a $55.00 target price (down from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Piper Sandler initiated coverage on Bristol-Myers Squibb in a report on Tuesday, April 22nd. They set an “overweight” rating and a $65.00 price target on the stock. Wall Street Zen downgraded Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 6th. Finally, Jefferies Financial Group dropped their price objective on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a “buy” rating for the company in a report on Wednesday, April 23rd. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $58.00.

Bristol-Myers Squibb Stock Performance

Shares of BMY opened at $50.13 on Thursday. The firm’s fifty day simple moving average is $48.87 and its two-hundred day simple moving average is $54.88. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.33. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. The stock has a market capitalization of $102.01 billion, a P/E ratio of -11.34, a price-to-earnings-growth ratio of 2.07 and a beta of 0.38.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.50 by $0.30. The business had revenue of $11.20 billion during the quarter, compared to analysts’ expectations of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The firm’s revenue was down 5.6% on a year-over-year basis. During the same quarter last year, the firm posted ($4.40) earnings per share. As a group, analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.